{"id":"NCT01710514","sponsor":"Ferring Pharmaceuticals","briefTitle":"A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment","officialTitle":"A Multi-Center, Randomized, Open-Label, Parallel Group Study of FE 999913 Vaginal Tablet 100 mg in Japanese Female Patients Undergoing Fertility Treatment [In Vitro Fertilization/Embryo Transfer (IVF-ET)]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2012-10-19","resultsPosted":"2014-08-19","lastUpdate":"2014-09-05"},"enrollment":108,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Luteal Hormone Supplementation"],"interventions":[{"type":"DRUG","name":"FE 999913 vaginal tablet","otherNames":[]}],"arms":[{"label":"FE 999913 100 mg BID","type":"ACTIVE_COMPARATOR"},{"label":"FE 999913 100 mg TID","type":"ACTIVE_COMPARATOR"}],"summary":"The purposes of the study are to verify sufficient supplementation of luteal hormone after administrating FE999913 Vaginal Tablet twice a day (BID) or three times a day (TID) and to determine the efficacy and safety of FE999913 Vaginal Tablet in Japanese women undergoing fertility treatment with IVF-ET (a fresh embryo transfer).","primaryOutcome":{"measure":"The Proportion of Subjects With Blood Progesterone Concentration Not Less Than 10 ng/ml","timeFrame":"Day 5 of treatment","effectByArm":[{"arm":"FE999913 000072 (BID/TID)","deltaMin":98.9,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":19},"locations":{"siteCount":6,"countries":["Japan"]},"refs":{"pmids":["26457065"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":54},"commonTop":["Ovarian hyperstimulation syndrome","Abdominal distension","Genital haemorrhage","Constipation","Nasopharyngitis"]}}